ストックスクリーナーアプリを入手
0.9263
3.13%
-0.0299
アフターアワーズ：
.93
0.0037
+0.40%
前日終値:
$0.9562
開ける：
$0.9562
24時間の取引高:
77,530
Relative Volume:
0.27
時価総額：
$20.00M
収益：
-
当期純損益:
$-8.29M
株価収益率:
-1.3233
EPS:
-0.7
ネットキャッシュフロー:
$-6.47M
1週間 パフォーマンス:
-7.37%
1か月 パフォーマンス:
+8.98%
6か月 パフォーマンス:
-37.83%
1年 パフォーマンス:
-24.69%
1日の値動き範囲:
$0.9145
$0.97
1週間の範囲:
$0.9145
$1.05
52週間の値動き範囲:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Compare NNVC vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
0.9263 | 20.65M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-16 | 開始されました | Alliance Global Partners | Buy |
| 2015-02-11 | 開始されました | Midtown Partners | Strong Buy |
NanoViricides Inc (NNVC) 最新ニュース
NNVC Earnings History & Surprises | EPS & Revenue Results | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
getLinesFromResByArray error: size == 0 What is NanoViricides Inc.’s TAM (Total Addressable Market)Portfolio Gains Report & Growth Focused Entry Reports - mfd.ru
US Stocks Recap: Is NanoViricides Inc forming a breakout patternJuly 2025 WrapUp & Community Trade Idea Sharing - baoquankhu1.vn
Aug Fed Impact: Can NanoViricides Inc continue delivering strong returnsQuarterly Earnings Report & Long-Term Safe Investment Plans - baoquankhu1.vn
NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387ICYMI - Proactive financial news
Growth Value: Will NanoViricides Inc benefit from rate cutsJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Small cap wrap: Aftermath Silver, M2i Global, NanoViricides, AtaiBeckley… - Proactive financial news
NanoViricides advances toward fully funded Phase II MPox trial in DRC - Proactive financial news
NanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox study - Yahoo Finance
NanoViricides: Fiscal Q2 Earnings Snapshot - kare11.com
NanoViricides: Fiscal Second Quarter Earnings Overview - Bitget
Moving Averages: Is NanoViricides Inc exposed to political riskJuly 2025 Movers & Growth Focused Stock Reports - baoquankhu1.vn
Can NanoViricides Inc grow without external fundingJuly 2025 Review & Growth Focused Stock Reports - baoquankhu1.vn
Small cap wrap: BioVie, VivoPower, NanoViricides, Aftermath Silver... - Proactive financial news
NanoViricides seeks FDA orphan status for MPox drug - Yahoo Finance
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Bitget
New Mpox drug candidate NV-387 chases FDA orphan status - Stock Titan
NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX) - Barchart.com
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza WaveNV-387 is Effective Against H3N2 - Ventura County Star
Small cap wrap: Medicus Pharma, 1911 Gold, NanoViricides, Nextech3D.ai, NextSource Materials… - Proactive Investors
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - USA Today
NanoViricides seeks orphan drug status with US FDA for measles treatment - Yahoo Finance
Measles cases surge as NanoViricides seeks orphan status for NV-387 - Stock Titan
NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres - USA Today
Trading Recap: Is NanoViricides Inc part of any ETFJuly 2025 Drop Watch & Real-Time Buy Signal Alerts - baoquankhu1.vn
CEO Change: Is NanoViricides Inc undervalued by DCF analysisWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Reno Gazette Journal
NanoViricides President Discusses Broad-Spectrum Antiviral Platform and Upcoming Phase II Trial for MPox Treatment - citybuzz -
NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres - accessnewswire.com
Inside a single antiviral drug aimed at flu, COVID, RSV and Mpox - Stock Titan
Can NanoViricides Inc. continue delivering strong returnsJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - mfd.ru
Can NanoViricides Inc continue delivering strong returnsQuarterly Growth Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - Hattiesburg American
NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference - chronicle-tribune.com
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - hattiesburgamerican.com
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles - Hattiesburg American
ETF Watch: Should I hold or sell NanoViricides Inc nowJuly 2025 Chart Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
NanoViricides Inc (NNVC) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):